NCT04632108进行中（未招募）1 期
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 199
- 试验地点
- 2
- 主要终点
- Number of participants with serious adverse events (SAE) as assessed by CTCAE v5.0
研究概览
简要总结
This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •According to RECIST 1.1 criteria, all patients must have at least one measurable lesion, and the tumor lesions must be accurately measured in at least one dimension, and lesions previously treated with radiotherapy or local therapy are only evaluated as non-target lesions. Bone metastatic lesions are not considered as measurable lesions;
- •ECOG performance status (PS) 0-1;
- •The results of the laboratory tests must meet all the following criteria:
- •（1）Haemoglobin≥9 g/dL；platelet count≥ 100 × 109/L；absolute neutrophil count≥ 1.5 × 109/L；
- •（2）Albumin≥ 3.0g/dL；total bilirubin ≤ 1.5 times the upper limit of normal (ULN)；aspartate transaminase and alanine aminotransferase≤ 2.5 times ULN if no demonstrable liver metastases ( ≤5 times ULN in the presence of liver metastases);
- •（3）Creatinine clearance≥ 50ml/min；
- •（4）Prothrombin time, international normalized ratio, and activated partial thromboplastin time≤1.5×ULN (except for patients receiving anticoagulant therapy)
- •4.Life expectancy of at least 3 months;
- •5.Patients who are supposed to be enrolled into the monotherapy dose escalation study must meet all the following criteria:
- •Patients of either gender, aged from 18 years old to 70;
- •Patients with histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic malignant solid tumor, for whom have no standard therapy or have no access to standard therapy for various reasons.
- •6.Patients who are supposed to be enrolled into the monotherapy dose expansion study must meet all the following criteria:
- •Patients of either gender, aged ≥ 18 years old；
- •Patients with histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer, for whom have no standard therapy or have no access to standard therapy for various reasons, and that tumor tissue samples are CLDN18.2 positive detected by central laboratory (medium-high expression)；
- •Other tumor types with good potential benefits will be included according to the results of the clinical results of same target products (CLDN18.2-positive tumors).
- •7.Patients who are supposed to be enrolled into the dose escalation of ASKB589 combined with chemotherapy should meet all the following criteria:
- •Patients of either gender, aged from 18 years old to
- •Patients with gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer who are tolerant to CAPOX, GEM+Nab-P chemotherapy.
- •Patients with gastric cancer, gastroesophageal junction adenocarcinoma who are intolerant to anti-human epidermal growth factor receptor 2 (anti-HER2) drug therapy.
- •Other tumor types with good potential benefits will be included according to the results of mono-therapy dose expansion and the clinical results of same target products.
- •8.Patients who are supposed to be enrolled into the dose expansion of ASKB589 combined with chemotherapy should meet all the following criteria:
- •Patients of either gender, aged ≥ 18 years old.
- •Patients with gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer who are tolerant to CAPOX, GEM+Nab-P chemotherapy, and that tumor tissue samples are CLDN18.2 positive detected by central laboratory.
- •Patients with gastric cancer, gastroesophageal junction adenocarcinoma that who are intolerant to anti-HER2 drug therapy.
- •Other tumor types with good potential benefits will be included according to the results of this study and the clinical results of same target products.
排除标准
- •Patients have a history of severe allergic reactions to monoclonal antibodies or are intolerance to monoclonal antibodies, or those who are allergic to experimental drug and any component of the drug.
- •Patients have received a treatment of whole blood or blood component transfusion or various growth factor treatments within 14 days prior to enrollment.
- •Patients have received anti-tumor therapy within 14 days prior to enrollment，including but not limited to radiotherapy, chemotherapy, targeted therapy, treatment with herbal medications or other treatments that have known antitumor activity . Patients who have undergone palliative radiotherapy for bone metastases and whose acute toxicity has returned to normal can be selected;
- •Patients have received systemic immunosuppressive therapy（such as systemic corticosteroids）within 14 days prior to enrollment. However, patients using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30mg per day of hydrocortisone or 10mg per day of prednisone) are allowed；patients are allowed to receive a single dose of systemic corticosteroids treatment；
- •Patients have participated in other clinical trials within 28 days prior to enrollment; patients who have participated monoclonal antibody clinical trials within 2 months prior to sign written informed consent form also cannot participate in this trial；
- •Patients have received major surgical operation within 28 days prior to enrollment or schedule to perform major surgery during the period of this clinical trial;
- •Patients have gastrointestinal diseases such as gastrinoma, duodenitis, gastric ulcer, duodenal ulcer, pancreatitis or upper gastrointestinal hemorrhage, caused by nonmalignant tumor (gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer)withinwithin 3 months prior to enrollment；Patients have gastric inlet and outlet obstruction or suspected obstruction within 1 months prior to enrollment；
- •Known to have irritable bowel syndrome, ulcerative colitis, Crohn's disease, gastric outlet obstruction, etc., or any other causes that can cause long-term chronic nausea,persistent repeated vomiting or diarrhea, and uncontrolled or severe gastrointestinal bleeding;
- •Have a history of diagnosed neurological or mental disorders, including epilepsy or dementia;
- •Patients with any other malignant tumors within the past 5 years, cured cervical carcinoma in situ, basal cell, or squamous cell skin cancer are not included;
- •Known active central nervous system (CNS) metastasis or suspected cancerous meningitis;
- •Uncontrollable third-space effusion in clinical practice, which is deemed unsuitable for enrollment by the researchers;
- •Patients currently suffering from diseases that affect intravenous injection and venous blood sampling;
- •Patients suffering from major cardiovascular diseases, including:
- •（1）Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months before the first drug treatment；
- •（2）History of clinically significant ventricular arrhythmia (such as sustained ventricular tachycardia, ventricular fibrillation or torsade de pointes)；
- •（3）Patients have an abnormality in the 12-lead electrocardiogram (ECG) including a Fridericia's corrected QT interval (QTcF) greater than 450 milliseconds (ms) (males) or greater than 470 ms (females).
- •（4）History or family history of congenital long QT syndrome；
- •（5）Cardiac arrhythmias requiring anti-arrhythmic drug therapy (patients suffering from atrial fibrillation >1 month before the first administration of drug can be selected according to the condition of patients);
- •（6）Left ventricular ejection fraction <50%；
- •15.Pregnant or lactating women; or women of childbearing age who have a positive blood pregnancy test during screening period; or women of childbearing age and their spouses who are unwilling to take effective contraceptive measures during the period of this clinical trial and within 6 months after the end of the clinical trial;
- •16.Patients who are not meet the inclusion criteria based on the judgment of investigator；
- •17.Patients included in dose-escalation and expansion study of combined chemotherapy should also exclude:
- •Patients with gastric cancer, gastroesophageal junction adenocarcinoma who are allergic, intolerant or contraindicated to any other components of capecitabine and oxaliplatin.
- •Patients with pancreatic cancer who are allergic, intolerant or contraindicated any components of gemcitabine and albumin bound paclitaxel for injection.
研究组 & 干预措施
ASKB589 Injection
Experimental
Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.
干预措施: ASKB589 Injection (Drug)
结局指标
主要结局
Number of participants with serious adverse events (SAE) as assessed by CTCAE v5.0
时间窗: up to 21 days following last dose
An SAE is defined as any untoward medical occurrence that, at any dose: a.) Results in death; b.) Is life-threatening; c.) Requires inpatient hospitalization or prolongation of existing hospitalization; d.) Results in persistent or significant disability/incapacity; e.) Is a congenital anomaly/birth defect; f.) Other important medical events; The number of participants who experience an SAE will be presented.
The incidence and case number of DLT (Dose Limiting Toxicity) during observation period
时间窗: up to 21 or 28 days following first dose
DLT is short for Dose Limiting Toxicity，dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Number of participants with adverse events as assessed by CTCAE v5.0
时间窗: up to 21 days following last dose
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be presented.
Maximum Tolerated Dose (MTD）
时间窗: up to 21 or 28 days following first dose
The MTD was defined as the highest dose of ASKB589 not causing DLT in more than 33% of patients in the first treatment cycle.
The recommended dose
时间窗: from date of treatment start until data cut-off, up to 2 years
The recommended dose will be determined during the dose escalation and dose expansion stage of the study.
Objective response rate
时间窗: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
Evaluation of objective response rate assessed by response evaluation criteria in solid tumors version 1.1(RECIST 1.1)
次要结局
- Pharmacokinetics:terminal elimination half life (T1/2)(Up to 21 days after injection)
- Pharmacokinetics:apparent volume of distribution (Vz/F)(Up to 21 days after injection)
- Pharmacokinetics:Area Under Curve (AUC)(Up to 21 days after injection)
- Pharmacokinetics: Mean ResidenceTime（MRT）(Up to 21 days after injection)
- Pharmacokinetics: plasma clearance rate (CL)(Up to 21 days after injection)
- Pharmacokinetics: steady-state peak concentration (Css_max)(Up to 21 days after injection)
- Pharmacokinetics: time to steady-state peak concentration (Tss_max)(Up to 21 days after injection)
- Pharmacokinetics: minimum value of steady plasma drug concentration（Css_min）(Up to 21 days after injection)
- Evaluation of immunogenicity(from date of treatment start until data cut-off, up to 2 years)
- Pharmacokinetics:maximum Plasma Concentration [Cmax](Up to 21 days after injection)
- Pharmacokinetics:time to maximum observed plasma concentration (Tmax)(Up to 21 days after injection)
- Pharmacokinetics:elimination rate constant（Kel）(Up to 21 days after injection)
- Objective response rate（ORR）(from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years)
- disease control rate（DCR）(from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years)
- Duration of Response（DOR）(from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years)
- Progression free survival（PFS）(from date of treatment start until the date of disease progression or until death due to any causes, up to 2 years.)
- Overall survival（OS）(from the date of treatment start until the documented date of death from any cause，up to 2 years.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn WoundsDeep Full-thickness Burn Injury (Disorder)NCT03695939XenoTherapeutics, Inc.25
Unknown
1 期
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C MutationAdvanced Solid TumorNCT05119933Shanghai YingLi Pharmaceutical Co. Ltd.55
招募中
1 期
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaRefractory Ewing SarcomaRelapsed Ewing SarcomaEwing SarcomaNCT05734066Jazz Pharmaceuticals60
已完成
1 期
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)Solid TumorNCT03085914Incyte Corporation70
进行中（未招募）
1 期
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Gastric CancerNCT05632939AskGene Pharma, Inc.62